LA
AUPH icon

Legacy Advisors’s Aurinia Pharmaceuticals AUPH Stock Holding History

Legacy Advisors’s Portfolio AUPH Stock Details AUPH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-42,500
Closed -$342K – 47
2025
Q1 		$342K Hold
42,500
– – 0.04% 304
2024
Q4 		$382K Hold
42,500
– – 0.04% 282
2024
Q3 		$312K Hold
42,500
– – 0.03% 294
2024
Q2 		$243K Hold
42,500
– – 0.03% 285
2024
Q1 		$213K Hold
42,500
– – 0.03% 292
2023
Q4 		$382K Hold
42,500
– – 0.05% 216
2023
Q3 		$330K Hold
42,500
– – 0.05% 226
2023
Q2 		$411K Hold
42,500
– – 0.06% 190
2023
Q1 		$466K Hold
42,500
– – 0.09% 156
2022
Q4 		$184K Hold
42,500
– – 0.03% 235
2022
Q3 		$320K Buy
+42,500
New +$368K 0.07% 166

Other funds holding AUPH

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Legacy Advisors's AUPH Position: Q2 2025 in Review

Legacy Advisors sold out of Aurinia Pharmaceuticals (AUPH) in Q2 2025, closing a stake of 42,500 shares — an estimated $342K sold.

Legacy Advisors first reported a position in AUPH in Q3 2022 and held it in 11 quarters. The position peaked at $466K in Q1 2023. 219 funds tracked by Wall St. Rank hold AUPH as of Q2 2025.

  • Legacy Advisors reported no remaining Aurinia Pharmaceuticals position as of Q2 2025 after selling out during the quarter.
  • Legacy Advisors sold 42,500 Aurinia Pharmaceuticals shares in Q2 2025, an estimated $342K.
  • Legacy Advisors first reported a position in Aurinia Pharmaceuticals in Q3 2022 and held it in 11 quarters.
  • Legacy Advisors's Aurinia Pharmaceuticals position peaked at $466K in Q1 2023.
  • 219 funds tracked by Wall St. Rank held Aurinia Pharmaceuticals as of Q2 2025.

Based on Legacy Advisors's 13F filing for Q2 2025, filed 7 Aug 2025.